|1.||Lawrence, Theodore S: 6 articles (04/2013 - 06/2010)|
|2.||Zhao, Lili: 5 articles (06/2012 - 06/2010)|
|3.||Parsels, Leslie A: 5 articles (06/2012 - 06/2010)|
|4.||Maybaum, Jonathan: 5 articles (06/2012 - 06/2010)|
|5.||Morgan, Meredith A: 5 articles (06/2012 - 06/2010)|
|6.||Zabludoff, Sonya D: 4 articles (06/2012 - 04/2010)|
|7.||Parsels, Joshua D: 4 articles (06/2012 - 06/2010)|
|8.||Simeone, Diane M: 3 articles (06/2012 - 06/2010)|
|9.||Agbo, Felix: 2 articles (03/2014 - 09/2013)|
|10.||Zabludoff, Sonya: 2 articles (03/2014 - 07/2010)|
04/01/2013 - "In vivo efficacy of AZD7762 demonstrated a dose-dependent inhibitory effect on GBM tumor growth rate and a reduction in tumor cellularity based on DW-MRI scans along with enhancement of radiation efficacy. "
03/01/2011 - "This model detected significant tumor regression in the AZD7762 + 1 Gy and GEM + 1 Gy that was not detected when comparing the tumor doubling times. "
04/01/2010 - "AZD7762 treatment enhanced the radiosensitivity of p53-mutated tumor cell lines (DMFs ranging from 1.6-1.7) to a greater extent than for p53 wild-type tumor lines (DMFs ranging from 1.1-1.2). "
10/01/2012 - "The clinical application of AZD7762, as an adjuvant in the radiotherapy of breast cancers, should be further explored."
06/15/2010 - "AZD7762 was also a radiation sensitizer in multiple tumor xenograft models. "
01/01/2014 - "The present study was aimed to assess the potential to use the Chk1 and Chk2 inhibitor, AZD7762, with other anticancer agents in chemotherapy to treat ovarian clear cell carcinoma. "
02/15/2012 - "We examined drug effects on DNA replication and killing of cancer cells and found that LMP-400 showed synergistic antiproliferative activity when combined with AZD7762 in human colon carcinoma cells. "
01/01/2014 - "The present study indicates that chemotherapy with AZD7762 and cisplatin should be explored as a treatment modality for women with ovarian clear cell carcinoma."
01/01/2014 - "Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary."
05/01/2013 - "PARP1 inhibitors [AZD2281 ; ABT888 ; NU1025 ; AG014699] interacted with CHK1 inhibitors [UCN-01 ; AZD7762 ; LY2603618] to kill mammary carcinoma cells. "
|3.||Breast Neoplasms (Breast Cancer)
10/01/2012 - "These results suggest that AZD7762 may effectively abrogate radiation-induced G2/M arrest and inhibit radiation damage repair in conferring radiosensitivity on p53 mutant T47D breast cancer cells, by promoting radiation-induced apoptosis and mitotic catastrophe. "
10/01/2012 - "However, whether or not AZD7762 sensitizes breast cancer cells to radiation has not been defined. "
10/01/2012 - "The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo."
10/01/2012 - "In the present study, we aimed to demonstrate for the first time, that AZD7762 not only promotes radiation-induced apoptosis and mitotic catastrophe of p53 mutant T47D breast cancer cells in vitro, but also delays their xenograft growth in response to radiation in vivo. "
01/01/2014 - "The Chk1 inhibitors V158411, PF-477736 and AZD7762 potently inhibited the proliferation of triple-negative breast cancer cells as well as ovarian cancer cells, and these cell lines were sensitive compared to ER positive breast and other solid cancer cells lines. "
|4.||Melanoma (Melanoma, Malignant)
|5.||Pancreatic Neoplasms (Pancreatic Cancer)
12/15/2011 - "We found that the combination of AZD7762 and olaparib produced significant radiosensitization in p53 mutant pancreatic cancer cells and in all of the isogenic cancer cell lines. "
12/15/2011 - "Thus, we hypothesized that inhibition of HRR (mediated by Chk1 via AZD7762) and PARP1 [via olaparib (AZD2281)] would selectively sensitize p53 mutant pancreatic cancer cells to radiation. "
06/01/2011 - "Together these data support the clinical investigation of AZD7762 with gemcitabine in pancreatic cancer under a dosing schedule in which gemcitabine is administered concurrent with or before AZD7762 and in conjunction with skin biopsies to measure pS345 Chk1."
06/01/2011 - "We tested multiple schedules of administration of gemcitabine and AZD7762 on the survival of pancreatic cancer cells. "
06/15/2010 - "Furthermore, they support the clinical use of AZD7762 in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer."
|6.||Checkpoint kinase 1
|7.||Tumor Suppressor Protein p14ARF (p14ARF)
|8.||Troponin T (T, Troponin)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)